Singapore, Sept. 2 -- Singapore is expanding subsidised access to Roche's Columvi, or glofitamab, for eligible patients with relapsed or refractory diffuse large B-cell lymphoma.

From 1 September 2026, Columvi will be included on the Ministry of Health's Cancer Drug List and Medication Assistance Fund.

The subsidy applies to eligible patients with relapsed or refractory DLBCL who are not candidates for autologous stem cell transplantation and who have received at least one prior therapy.

Under the Medication Assistance Fund, eligible Singapore citizens may receive subsidies of up to 75%, while eligible permanent residents may receive support of up to 20% at public healthcare institutions.

Columvi is a T-cell-engaging bispecific antibo...